Truist initiated coverage of NewAmsterdam Pharma (NAMS) with a Buy rating and $57 price target The stock significantly outperformed in 2024 and 2025 as the company successfully de-risked its lead asset, obicetrapib, with positive Phase 3 data, notes the analyst, who believes the upcoming mid-year PREVAIL cardiovascular outcomes trial timeline update, positive CVOT readout, and 2027 launch “could represent major near-term inflections.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAMS:
- NewAmsterdam Highlights Obicetrapib Progress in Investor Presentation
- Reaffirming Buy on NewAmsterdam Pharma: Optimized Expense Outlook and Milestone Upside Strengthen Risk‑Reward Profile
- NewAmsterdam Pharma management to meet virtually with Piper Sandler
- NewAmsterdam Pharma price target raised to $45 from $41 at Guggenheim
- NewAmsterdam Pharma (NAMS): Buy Rating on Strong PREVAIL Momentum, Broad Phase 3 Cardiovascular Program, and Solid Cash Runway